Welcome to our dedicated page for LAVA Therapeutics N.V. news (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on LAVA Therapeutics N.V. stock.
LAVA Therapeutics N.V. (LVTX) news coverage on this page centers on the company’s evolution as a clinical-stage immuno-oncology developer and its corporate transition following an acquisition by XOMA Royalty Corporation. Company press releases and SEC-linked announcements describe how LAVA advanced its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers, while also undertaking restructuring measures and a strategic review that ultimately led to a tender offer and change of control.
Readers can follow updates related to LAVA’s pipeline programs, including the internal candidate LAVA‑1266 for CD123+ hematologic malignancies and partnered Phase 1 programs JNJ‑89853413 with Johnson & Johnson and PF‑08046052 with Pfizer Inc. News items detail clinical trial progress, portfolio reprioritization, and decisions to discontinue earlier programs such as LAVA‑1207 and LAVA‑051. These releases provide insight into how the company focused its resources on select assets while maintaining key collaborations.
Another major theme in LVTX news is corporate and capital structure events. LAVA announced an evaluation of strategic options, workforce reductions, closure of Netherlands operations, and a waiver of an Innovation Credit repayment obligation from the Netherlands Enterprise Agency (RVO). Subsequent news and 8‑K references document the share purchase agreement with XOMA Royalty Corporation, amendments to the offer terms, shareholder approvals at an extraordinary general meeting, and the successful tender of a large majority of outstanding shares.
For investors researching LVTX historically, this news stream provides context on both the scientific direction of LAVA’s Gammabody® platform and the sequence of events that resulted in LAVA becoming a majority-owned subsidiary of XOMA Royalty Corporation and delisting from the Nasdaq Global Select Market. Bookmark this page to access archived announcements, transaction milestones, and program updates associated with the former LVTX listing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
LAVA Therapeutics N.V. (Nasdaq: LVTX) has announced promising clinical data from its ongoing Phase 1/2a trials for LAVA-051 and LAVA-1207, focusing on hematologic malignancies and metastatic castration-resistant prostate cancer. LAVA-051 demonstrated a favorable safety profile and initial anti-tumor activity in patients with chronic lymphocytic leukemia and multiple myeloma. Similarly, initial data for LAVA-1207 indicated a favorable safety profile with signs of clinical activity, including stabilized or decreased PSA levels in heavily pre-treated patients. Financially, LAVA reported a strong balance sheet with cash and investments totaling $132.9 million, expected to sustain operations through 2026. Additionally, a license agreement with Seagen for LAVA-1223 provides $50 million upfront and up to $650 million in potential milestones.